Caroline's Feed
Jun 22, 2015

Anthem confident, but experts see antitrust hurdles to Cigna deal

NEW YORK/WASHINGTON (Reuters) – U.S. health insurer Anthem Inc (ANTM.N: Quote, Profile, Research, Stock Buzz) on Monday dismissed concerns that buying smaller competitor Cigna Corp (CI.N: Quote, Profile, Research, Stock Buzz) would be considered anti-competitive, even as antitrust experts said the combination would earn regulatory scrutiny.

Any merger could require asset sales and would be complicated by other potential deals in the U.S. healthcare industry, expected to see rapid consolidation. Insurers have emerged from years of changes in health insurance under President Barack Obama’s national healthcare reform law and are seeking now to use scale to trim administrative costs and negotiate lower prices with doctors in their networks.

Jun 21, 2015

Anthem offers $47 billion for Cigna as insurers race for a deal

NEW YORK (Reuters) – U.S. health insurer Anthem Inc said on Saturday it had offered $47 billion in cash and stock for smaller rival Cigna Corp, signaling a pick-up in the industry’s long-awaited consolidation.

The biggest U.S. health insurers are seeking acquisitions to boost membership in government-paid healthcare plans and the employer-based insurance that is Cigna’s specialty. Being bigger can help them negotiate better prices and improved networks of doctors, they said.

Jun 20, 2015

Anthem offers $46 billion for Cigna, says CEO role holds up deal

NEW YORK (Reuters) – U.S. health insurer Anthem Inc (ANTM.N: Quote, Profile, Research, Stock Buzz) said on Saturday it had offered $46 billion in cash and stock for smaller rival Cigna Corp (CI.N: Quote, Profile, Research, Stock Buzz) but that the deal was stalled over Cigna CEO David Cordani’s role in the merged company.

The announcement comes as the biggest U.S. health insurers seek acquisitions to boost membership in government-paid healthcare plans and the employer-based insurance that is Cigna’s specialty. They say being bigger can help them negotiate for better prices and improved networks of doctors.

Jun 17, 2015

No ready fix if Obamacare subsidies are lost: policy experts

BOSTON/NEW YORK (Reuters) – U.S. lawmakers and governors are unlikely to act to restore Obamacare health insurance subsidies in at least 34 states should the Supreme Court rule them illegal, health policy experts said on Wednesday.

The influence of elections in 2016 as well as restrictions already put in place in states opposed to President Barack Obama’s health law could hamper even a short-term compromise, experts said during a panel discussion in Boston at The Forum at Harvard T.H. Chan School of Public Health, presented in collaboration with Reuters.

Jun 17, 2015

Insight – Economists predict shockwaves if Obamacare subsidies are nixed

NEW YORK (Reuters) – As the U.S. Supreme Court prepares to rule on whether people in 34 states can continue to receive Obamacare health insurance subsidies, economists are projecting billions of dollars in lost healthcare spending for hospitals, drugstores and drugmakers if the justices say the payments are illegal.

The immediate consequences of such a ruling would fall on the 6.4 million people who receive the subsidies and live in states that did not establish their own insurance exchanges under President Barack Obama’s healthcare law, instead relying on the federal HealthCare.gov website.

Jun 17, 2015

Economists predict shockwaves if Obamacare subsidies are nixed

NEW YORK (Reuters) – As the U.S. Supreme Court prepares to rule on whether people in 34 states can continue to receive Obamacare health insurance subsidies, economists are projecting billions of dollars in lost healthcare spending for hospitals, drugstores and drugmakers if the justices say the payments are illegal.

The immediate consequences of such a ruling would fall on the 6.4 million people who receive the subsidies and live in states that did not establish their own insurance exchanges under President Barack Obama’s healthcare law, instead relying on the federal HealthCare.gov website.

Jun 5, 2015

Insight – Amazon, Google race to get your DNA into the cloud

NEW YORK (Reuters) – Amazon.com Inc is in a race against Google Inc to store data on human DNA, seeking both bragging rights in helping scientists make new medical discoveries and market share in a business that may be worth $1 billion (651.30 million pounds) a year by 2018.

Academic institutions and healthcare companies are picking sides between their cloud computing offerings – Google Genomics or Amazon Web Services – spurring the two to one-up each other as they win high-profile genomics business, according to interviews with researchers, industry consultants and analysts.    

Jun 5, 2015

Amazon, Google race to get your DNA into the cloud

NEW YORK (Reuters) – Amazon.com Inc is in a race against Google Inc to store data on human DNA, seeking both bragging rights in helping scientists make new medical discoveries and market share in a business that may be worth $1 billion a year by 2018.

Academic institutions and healthcare companies are picking sides between their cloud computing offerings – Google Genomics or Amazon Web Services – spurring the two to one-up each other as they win high-profile genomics business, according to interviews with researchers, industry consultants and analysts.    

Jun 4, 2015

As Supreme Court Obamacare case looms, Republicans split on response

WASHINGTON/NEW YORK (Reuters) – U.S. Republicans face a potential political backlash from voters if the Supreme Court rules soon against President Barack Obama’s healthcare law, and are split over what to do about it, with some calling on the Obama administration for help.

But the White House, perhaps sensing a chance to blame Republicans for trouble, is showing no outward signs of crafting a contingency plan in case of an adverse outcome in King v. Burwell, expected to be ruled on by the end of this month.

May 29, 2015

Bristol-Myers sues immunotherapy exec who left for AstraZeneca

- NEW YORK, May 29 (Reuters) – Bristol-Myers
Squibb
has sued a top cancer immunotherapy executive for violating
confidentiality and non-compete agreements after he left for
direct competitor AstraZeneca, court documents show.

The suit, filed in Delaware’s Court of Chancery late on
Thursday, said that David Berman violated agreements that
prevented him from using confidential and trade secret
information when he accepted a job at AstraZeneca, which is also
developing treatments that use the immune system to fight
cancer.